Newly expanded Prostate cancer drugs It can bring new hope to patients with common diseases.
Novartis, a Swiss-based pharmaceutical company, announced on March 28 that the US Food and Drug Administration (FDA) had expanded its approval for Pluvicto (Lutetium lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT) administered prior to chemotherapy.
(RLT is a type of targeted nuclear medicine used by doctors for multiple treatments. Types of canceraccording to Novartis. )
The risk of prostate cancer increases by 45% among men who share one nasty behavior
The drug is targeted in patients with PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) who have received a round of androgen receptor inhibitors (ARPI), a class of drugs used to treat metastatic prostate cancer.
New and expanded prostate cancer drugs could bring new hope to patients with common diseases. (istock)
Pluvicto first received FDA approval on March 23, 2022, but this new expanded approval triples the number of eligible patients I’ll receive the medicineAccording to a press release from Novartis.
This drug is administered through IV into the bloodstream where it adheres to prostate cancer cells and kills them without replicating or killing them.
This US prostate cancer case is skyrocketing as doctors probably share the reason
“Pluvicto’s previous indications could actually change the treatment paradigm for patients with MCRPC,” said Michael Morris, Maryland, head of the prostate cancer section at Memorial Sloan Kettering Cancer Center in New York.
“It provides targeted therapy that slows disease progression better compared to the second ARPI. This approval should open entrances and exits to treatments that progress with one ARPI and have clear clinical benefits for patients with MCRPC who have not received chemotherapy.”
In clinical trials, Pluvicto “significantly reduced the risk of progression or death.”
This is a type of prostate cancer that spreads to other parts of the body and does not respond to standard hormonal therapy, according to WebMD.
The levels of prostate-specific membrane antigen (PSMA), a protein produced by prostate cancer cells, are also increasing.
in Clinical trialsPluvicto “significantly reduced the risk of progression or death” in patients with MCRPC, Novartis reported.
image
“FDA expanded approval [lutetium Lu 177 vipivotide tetraxetan] It marks a transformative step in the treatment of MCRPC and highlights the growing impact of precision oncology.
Click here to get the Fox News app
“By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only expanding treatment options, but also redefining standard care for PSMA-positive diseases.”
“By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only expanding treatment options, but also redefining standard care for PSMA-positive diseases,” the researchers said. (istock)
Prostate cancer is the second major cause Death among menMCRPC accounts for most deaths and 20% of all metastatic prostate cancer cases.
Studies show that approximately 10% to 20% of patients with prostate cancer develop MCRPC within five years of initial treatment, and cases of metastatic patients have increased by 4% to 5% each year since 2011.
Click here to sign up for our health newsletter
60% of prostate cancer are diagnosed in men Over 65 years oldAccording to the American Cancer Society. The risk of being diagnosed with metastatic prostate cancer usually occurs between 65 and 74.
Side effects of Pluvicto included dry mouth (61%), fatigue (53%), nausea (32%), and constipation (22%).
Prostate cancer is the second major cause of death in men. MCRPC accounts for most deaths and 20% of all metastatic prostate cancer cases. (istock)
Patients who received the medication were able to proceed after taking chemotherapy.
Novartis is committed to delivering Pluvicto to nearly 600 RLT treatment sites in the US, the company said.
Visit us for more health articles www.foxnews.com/health
Looking ahead, Novartis said it plans to investigate the use of RLT for other types of advanced cancer, such as the breast, colon, neuroendocrine and lungs. Pancreatic cancer.
